A J Connor1, S G Fraser2. 1. Department of Ophthalmology, Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear, UK. 2. Sunderland Eye Infirmary, Sunderland, Tyne and Wear, UK.
Abstract
PURPOSE: In 2009, the National Institute for Clinical Excellence (NICE) published guidance on the treatment of ocular hypertension and glaucoma. The aim of the present study was to describe the impact this guidance had on glaucoma prescribing and to describe recent prescribing trends in England. METHOD: Prescribing cost analysis data held by NHS Business Authority for the years 2000-2012 was analysed. RESULTS: The number of prescriptions dispensed increased by 67% from 4.76 million in 2000 to 7.96 million in 2012. Over the same time period, drug costs increased by 88% from £55.2 million to £103.7 million. Prescriptions for prostaglandin analogues increased fourfold, while there was a threefold decrease in the use of beta-blockers. The most commonly prescribed glaucoma medication was latanoprost. The introduction of generic latanoprost in 2012 more than halved the cost associated with this medication. NICE guidance appeared to have had no effect on the total number of prescriptions or the classes of medications prescribed. CONCLUSION: The introduction of the NICE guidelines did not change glaucoma prescribing practice, although it is not clear whether this represents non-adherence to the guidelines or whether the guidelines embodied pre-existing practice.
PURPOSE: In 2009, the National Institute for Clinical Excellence (NICE) published guidance on the treatment of ocular hypertension and glaucoma. The aim of the present study was to describe the impact this guidance had on glaucoma prescribing and to describe recent prescribing trends in England. METHOD: Prescribing cost analysis data held by NHS Business Authority for the years 2000-2012 was analysed. RESULTS: The number of prescriptions dispensed increased by 67% from 4.76 million in 2000 to 7.96 million in 2012. Over the same time period, drug costs increased by 88% from £55.2 million to £103.7 million. Prescriptions for prostaglandin analogues increased fourfold, while there was a threefold decrease in the use of beta-blockers. The most commonly prescribed glaucoma medication was latanoprost. The introduction of generic latanoprost in 2012 more than halved the cost associated with this medication. NICE guidance appeared to have had no effect on the total number of prescriptions or the classes of medications prescribed. CONCLUSION: The introduction of the NICE guidelines did not change glaucoma prescribing practice, although it is not clear whether this represents non-adherence to the guidelines or whether the guidelines embodied pre-existing practice.
Authors: Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon Journal: Arch Ophthalmol Date: 2002-06
Authors: J M Burr; G Mowatt; R Hernández; M A R Siddiqui; J Cook; T Lourenco; C Ramsay; L Vale; C Fraser; A Azuara-Blanco; J Deeks; J Cairns; R Wormald; S McPherson; K Rabindranath; A Grant Journal: Health Technol Assess Date: 2007-10 Impact factor: 4.014
Authors: Tianjing Li; Kristina Lindsley; Benjamin Rouse; Hwanhee Hong; Qiyuan Shi; David S Friedman; Richard Wormald; Kay Dickersin Journal: Ophthalmology Date: 2015-10-31 Impact factor: 12.079
Authors: Claude Pinnock; Jennifer L Y Yip; Anthony P Khawaja; Robert Luben; Shabina Hayat; David C Broadway; Paul J Foster; Kay-Tee Khaw; Nick Wareham Journal: Ophthalmic Epidemiol Date: 2016-08-23 Impact factor: 1.648